학술논문

PAI‐1 gain‐of‐function genotype, factors increasing PAI‐1 levels, and airway obstruction: The GALA II Cohort
Document Type
article
Source
Clinical & Experimental Allergy. 47(9)
Subject
Biomedical and Clinical Sciences
Immunology
Lung
Genetics
Prevention
Clinical Research
Asthma
Aetiology
2.1 Biological and endogenous factors
Respiratory
Adolescent
Adult
Airway Obstruction
Alleles
Asthma
Occupational
Child
Cohort Studies
Ethnicity
Female
Gain of Function Mutation
Genetic Association Studies
Genetic Predisposition to Disease
Genotype
Humans
Male
Odds Ratio
Plasminogen Activator Inhibitor 1
Polymorphism
Single Nucleotide
Respiratory Function Tests
Young Adult
asthma
epidemiology
PAI-1
pediatrics
Nutrition and Dietetics
Public Health and Health Services
Allergy
Language
Abstract
BackgroundPAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.ObjectiveWe sought to determine whether the association of a gain-of-function polymorphism in plasminogen activator inhibitor-1 (PAI-1) with airway obstruction is modified by asthma status, and whether any genotype effect persists after accounting for common exposures that increase PAI-1 level.MethodsWe studied 2070 Latino children (8-21y) with genotypic and pulmonary function data from the GALA II cohort. We estimated the relationship of the PAI-1 risk allele with FEV1/FVC by multivariate linear regression, stratified by asthma status. We examined the association of the polymorphism with asthma and airway obstruction within asthmatics via multivariate logistic regression. We replicated associations in the SAPPHIRE cohort of African Americans (n=1056). Secondary analysis included the effect of the at-risk polymorphism on postbronchodilator lung function.ResultsThere was an interaction between asthma status and the PAI-1 polymorphism on FEV1 /FVC (P=.03). The gain-of-function variants, genotypes (AA/AG), were associated with lower FEV1 /FVC in subjects with asthma (β=-1.25, CI: -2.14,-0.35, P=.006), but not in controls. Subjects with asthma and the AA/AG genotypes had a 5% decrease in FEV1 /FVC (P